Skip to content

ED95 and ET95 of remazolam combined with remifentanil for inhibiting the response to painless gastroscopy access in elderly patients: a quantitative efficacy study with the biased-coin up and down method the response to painless gastroscopy access in elderly patients: a quantitative efficacy study with the biased-coin up and down method

ED95 and ET95 of remazolam combined with remifentanil for inhibiting the response to painless gastroscopy access in elderly patients: a quantitative efficacy study with the biased-coin up and down method the response to painless gastroscopy access in elderly patients: a quantitative efficacy study with the biased-coin up and down method

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094374
Enrollment
Unknown
Registered
2024-12-20
Start date
2025-07-25
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscope for elderly patients

Interventions

one group:Increase or decrease the dose of remazolam by a gradient

Sponsors

Hainan General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) gender is not limited, the patient's age is 65~80 years old, body mass index (BMI) 18~26kg/m2, American Society of Anesthesiologists (ASA) classification I~II; 2) New York Heart Association (NYHA) cardiac function classification ?~II; 3) gastroscopy time is not more than 15min; 4) the patient's sanity is clear, and he or she clearly understands and voluntarily participates in the study, and voluntarily signs the informed consent form to cooperate with the experimental test.

Exclusion criteria

Exclusion criteria: (1) patients requiring complex endoscopic techniques for diagnosis and treatment; (2) those with intention of endotracheal intubation; (3) those with difficulty in respiratory management; (4) patients with a diagnosis of grade 3 or higher hypertension who do not have satisfactory blood pressure control with antihypertensive medications; (5) patients with severe heart, brain, lung, liver, kidney, Parkinson's disease, diabetes mellitus, and other disorders; (6) chronic opioid users or history of psychotropic medication use; (7) Patients with preoperative cognitive dysfunction; (8) those with a seated systolic blood pressure of less than 90 mmHg during screening; (9) those who are allergic to or have contraindications to benzodiazepines, opioids, propofol, or lidocaine; and (10) those who have participated in a clinical trial of another drug within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Whether the patient experienced choking or somatic reaction during gastroscope placement via the pharynx;

Secondary

MeasureTime frame
Heart rate,HR;Blood pressure,BP;saturation of pulse oxygen,SPO2;bispectral index, BIS;modified observer's assessment of awareness/sedation,MOAA/S;

Countries

China

Contacts

Public ContactWang Lin

Hainan General Hospital

wanglin_0123@163.com+86 187 8988 7338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026